This study will test the experimental drug, ZEN003694, in combination with a marketed drug, talazoparib (Talzenna®), in patients with triple negative breast cancer (TNBC). Among the questions it will seek to answer are: 1. What are well-tolerated doses of ZEN003694 and talazoparib that can be given together without causing significant side effects? 2. What are the side effects of ZEN003694 when combined with talazoparib?

You may be eligible for this study if you meet the following criteria:

• Conditions: breast cancer
• Age: 99 years or below
• Gender: All